← Eichor
Study identifier: NCT06359795 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Exploring the Value of 18F-AlF-FAPI PET/CT in Assessing the Activity of Thyroid Eye Disease

Condition: Thyroid Eye Disease  ·  Sponsor: Peking University Third Hospital

PhaseNA
Planned participants50
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersYes

About this study

FAPI PET has been developed as a promising approach for the evaluation of fibroinflammatory, such as in inflammatory bowel disease. This prospective study aims to explore the value of 18F-AlF-FAPI PET/CT in assessing the activity of Thyroid Eye Disease (TED) and investigate whether FAPI PET/CT may be superior to 99mTc-DTPA SPECT/CT for the diagnosis, therapy response assessment, and follow-up of TED.

This description comes directly from the study's public registry record.

Talk to the study team

Hui Li, Dr.  ·  86-13121136769  ·  huilee1990@163.com

Lingge Suo, Dr.  ·  86-010-82264935  ·  suolingge_1019@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

Dept. of Nuclear Medicine, Peking University Third HospitalBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06359795